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OBSERVATIONS
Does Therapy With
Anti–TNF-a Improve
Glucose Tolerance
and Control in
Patients With Type 2
Diabetes?
T
ype 2 diabetes is associated with in-
sulin resistance (IR). IR is partially
caused by the cytokine tumor necro-
sis factor-a (TNF-a), which is produced
ininﬂammatoryfattissueinmuscle,liver,
and adipose tissue. Inﬂamed abdominal
fat releases adipokines and inﬂammatory
cytokines, one of which is TNF-a.P a s t
experimental studies using anti–TNF-a
therapy in type 2 diabetic patients have
been limited in both time and dosage be-
cause of the toxicity of these agents.
We designed a retrospective study in
which anti–TNF-a agents were used in
larger therapeuticdosesforupto10 years
in patients with rheumatoid arthritis
(RA) and Crohn’s disease (CR). We as-
sessed the effects of this treatment on
control of type 2 diabetes. Eight Veterans
Affairs patients with RA or CR and type 2
diabetes and a matched group of control
patients with both diagnoses were studied
over 10 years by chart review before and
after anti–TNF-a therapy. In order to as-
sess the effect of anti–TNF-a prescription
on glucose tolerance, we averaged blood
glucose for each treatment patient before
and during the last year of treatment.
The anti–TNF-a medications used were
entanercept by injection of 50 mg each
week and inﬂiximab as a large intravenous
bolus every 6–8 weeks.
We assessed control of diabetes using
fasting blood glucose (FBG), HbA1c,a n d
fasting plasma triglyceride (TG) values.
Eight patients had an average FBG of
142 mg/dL before treatment; after initia-
tion of treatment, the average FBG was
126 mg/dL, P , 0.01; and in the last full
year of treatment, FBG was 121 mg/dL,
P , 0.01. In select cases, average HbA1c
was 6.5% before and 5.5% after treat-
ment, and TGs were 350 mg/dL before
versus 200 mg/dL after therapy, and un-
changed in control subjects with CR.
Thus, patients with RA or CR and type 2
diabetes, who were also receiving anti–
TNF-a treatment for their autoimmune
disease, had signiﬁcant improvement in
their FBG, HbA1c,a n dT Gv a l u e s .K n o w -
ing that TNF-a is produced by oxidative
stress in fat imbedded in skeletal muscle
and liver, these results make a powerful
case for endogenous TNF-a being a caus-
ative factor in the IR of type 2 diabetes.
Many studies have demonstrated the
ability of TNF-a to induce IR (1,2). The
mostsuccessfulofthesehavebeeninvitro
or small animal experiments, including
many from our own laboratories (1,2).
Doseofanti–TNF-atherapyandduration
of treatment has been minimal in most of
these studies because of thetoxicity ofthe
drugs (3). Despite the limitations caused
by a retrospective study and lack of closer
monitoring of patients’ diabetes, our data
has value. It not only shows before and
after with highly matched control sub-
jects, but also examines higher doses of
anti–TNF-a agents and longer duration
of treatment. This provides an experi-
mental design that is able to identify a
role of TNF-a as a major effecter of IR in
humans with type 2 diabetes. It is clear
that more studies will be needed, partic-
ularly prospective studies, to solidify our
results.
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